NZ512942A - Polynucleotides encoding the IL-13 binding chains of the interleukin receptor, pharmaceutical compositions comprising the protein and methods of identifying inhibitors - Google Patents

Polynucleotides encoding the IL-13 binding chains of the interleukin receptor, pharmaceutical compositions comprising the protein and methods of identifying inhibitors

Info

Publication number
NZ512942A
NZ512942A NZ512942A NZ51294299A NZ512942A NZ 512942 A NZ512942 A NZ 512942A NZ 512942 A NZ512942 A NZ 512942A NZ 51294299 A NZ51294299 A NZ 51294299A NZ 512942 A NZ512942 A NZ 512942A
Authority
NZ
New Zealand
Prior art keywords
protein
methods
pharmaceutical compositions
polynucleotides encoding
interleukin receptor
Prior art date
Application number
NZ512942A
Other languages
English (en)
Inventor
Mary Collins
Debra Donaldson
Lori Fitz
Tamlyn Neben
Matthew J Whitters
Clive Wood
Marsha Wills-Karp
Original Assignee
Univ Johns Hopkins
Inst Genetics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22786499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ512942(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins, Inst Genetics Llc filed Critical Univ Johns Hopkins
Publication of NZ512942A publication Critical patent/NZ512942A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ512942A 1998-12-14 1999-12-13 Polynucleotides encoding the IL-13 binding chains of the interleukin receptor, pharmaceutical compositions comprising the protein and methods of identifying inhibitors NZ512942A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21133598A 1998-12-14 1998-12-14
PCT/US1999/029493 WO2000036103A1 (en) 1998-12-14 1999-12-13 Cytokine receptor chain

Publications (1)

Publication Number Publication Date
NZ512942A true NZ512942A (en) 2004-01-30

Family

ID=22786499

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ512942A NZ512942A (en) 1998-12-14 1999-12-13 Polynucleotides encoding the IL-13 binding chains of the interleukin receptor, pharmaceutical compositions comprising the protein and methods of identifying inhibitors

Country Status (16)

Country Link
US (1) US7507706B1 (enExample)
EP (1) EP1141286B1 (enExample)
JP (3) JP5519087B2 (enExample)
CN (2) CN1352686A (enExample)
AT (1) ATE342976T1 (enExample)
AU (1) AU780031B2 (enExample)
BR (1) BR9916209A (enExample)
CA (1) CA2356779C (enExample)
CY (1) CY1107657T1 (enExample)
DE (1) DE69933696T2 (enExample)
DK (1) DK1141286T3 (enExample)
ES (1) ES2277460T3 (enExample)
MX (1) MXPA01006006A (enExample)
NZ (1) NZ512942A (enExample)
PT (1) PT1141286E (enExample)
WO (1) WO2000036103A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
EP1333850B1 (en) * 2000-10-20 2008-08-20 Genetics Institute, Inc. Use of il-13 inhibitors for the treatment of tumors
JP2006516035A (ja) * 2003-01-17 2006-06-15 チルドレンズ ホスピタル メディカル センター アレルギー治療におけるｔｆｆ２、またはｔｆｆ２誘導剤の使用
US20040198686A1 (en) * 2003-01-18 2004-10-07 Rothenberg Marc Elliot Regulation of allergen induced gene
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
WO2004092404A2 (en) * 2003-04-11 2004-10-28 Wyeth Inhibitors of acidic mammalian chitinase as asthma therapeutics
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US20070178520A1 (en) * 2004-02-27 2007-08-02 Barbara Wolff-Winiski Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
US20090068195A1 (en) * 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
WO2008153790A2 (en) * 2007-05-29 2008-12-18 University Of Cincinnati Methods of modulating inflammation and compositions therefore
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
JP7657548B2 (ja) 2017-04-21 2025-04-07 エランコ・ユーエス・インコーポレイテッド 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
WO1991009059A1 (en) 1989-12-20 1991-06-27 Schering Corporation Antibody antagonists of human interleukin-4
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5246701A (en) 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
HU217099B (hu) 1991-03-29 1999-11-29 Elf Sanofi Sa. Eljárás citokin típusú aktivitással rendelkező fehérje, azt kódoló rekombináns DNS-szekvencia és a megfelelő transzformált sejtek és mikroorganizmusok előállítására
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
EP0656947A1 (en) 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
CN1127351C (zh) 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5696234A (en) 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
ES2334408T3 (es) 1995-10-23 2010-03-09 Zenyth Operations Pty Ltd Receptor de hematopoyetina y secuencias geneticas que lo codifican.
FR2742156A1 (fr) * 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU2326097A (en) 1996-03-13 1997-10-01 Zymogenetics Inc. Cytokine-receptor expressed in testis cells
WO1997047742A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
EP0812913A3 (en) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
AU6175696A (en) 1996-06-12 1998-01-07 Human Genome Sciences, Inc. Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
CN1572325A (zh) 1997-01-10 2005-02-02 拜奥根Idec马萨诸塞公司 用抗cd40l化合物治疗狼疮性肾炎
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
GB9723553D0 (en) 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
WO2000078336A1 (en) 1999-06-21 2000-12-28 Genetics Institute, Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
WO2001023410A2 (en) 1999-09-28 2001-04-05 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin 13 gene
JP2003511019A (ja) 1999-10-06 2003-03-25 ザ ペン ステート リサーチ ファウンデーション Ｉｌ１３変異体
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos

Also Published As

Publication number Publication date
BR9916209A (pt) 2001-12-26
CN1352686A (zh) 2002-06-05
EP1141286A4 (en) 2002-06-26
DK1141286T3 (da) 2007-02-19
JP2014113165A (ja) 2014-06-26
EP1141286A1 (en) 2001-10-10
CA2356779A1 (en) 2000-06-22
CY1107657T1 (el) 2013-04-18
PT1141286E (pt) 2007-01-31
CN104611339A (zh) 2015-05-13
ES2277460T3 (es) 2007-07-01
EP1141286B1 (en) 2006-10-18
ATE342976T1 (de) 2006-11-15
MXPA01006006A (es) 2004-08-12
AU2177500A (en) 2000-07-03
WO2000036103A9 (en) 2002-04-11
DE69933696D1 (de) 2006-11-30
JP5519087B2 (ja) 2014-06-11
WO2000036103A1 (en) 2000-06-22
JP2003511007A (ja) 2003-03-25
US7507706B1 (en) 2009-03-24
JP2010263889A (ja) 2010-11-25
CA2356779C (en) 2012-03-13
AU780031B2 (en) 2005-02-24
DE69933696T2 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
NZ500253A (en) Osteoprotegerin binding proteins and receptors
IL142905A0 (en) Functional antagonists of hedgehog activity
ATE269902T1 (de) Cytokinähnliches polypeptid-10 aus säugetieren
EA201070623A1 (ru) Конструкция из полипептидов однодоменных антител, применение композиции, ее содержащей, и способ лечения ревматоидного артрита
UA40621C2 (uk) Моноклональне антитіло, гібридомна клітинна лінія, поліпептид (варіанти), фрагмент днк (варіанти), фармацевтична композиція, спосіб одержання моноклонального антитіла
NZ515464A (en) Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
PL343245A1 (en) Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
MXPA03003902A (es) Polipeptidos de proquineticina, composiciones relacionadas y metodos.
MXPA01006006A (es) Cadena receptora de citocina.
IL127595A0 (en) Polypeptides capable of forming antigen binding structures with specificity for the rhesus D antigens the DNA encoding them and the process for their preparation and use
CA2354153A1 (en) Compounds and methods for modulating activation of nf-.kappa.b
CA2375605A1 (en) Peptide leukotriene receptor
ATE141283T1 (de) Verfahren zur reinigung eines hochglykosylierten proteins
WO2001036626A3 (en) Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds
GB9416536D0 (en) Orphan receptor
PL321890A1 (en) Variants human dnase i
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
WO2003025179A1 (fr) Nouveau polypeptide, adn associe et utilisation de ce polypeptide
WO2002072753A3 (en) Thymidylate synthase peptides that bind to thymidylate synthase messenger rna
EP0960935A4 (en) NEW CXC MURIN CHIMIOKIN RECEPTOR
WO2003044159A9 (en) Zinc finger proteins, polynucleotides encoding same and antibodies thereto
MX9700199A (es) Composiciones de cadena invariante utiles para tratar enfermedades autoinmunes.
NZ606260A (en) Novel polypeptides involved in immune response
MX9806628A (es) Gen de respuesta de diferenciacion terminal mieloide humana novedoso.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 13 DEC 2019 BY COMPUTER PACKAGES INC.

Effective date: 20121227

EXPY Patent expired